阿尔茨海默病手术疗法突然被叫停，相关专家回应：还在临床，未正式收费

Core Viewpoint - The existence of functional lymphatic vessels in the meninges has been confirmed, leading to the emergence of a therapy called "Lymphatic-Venous Anastomosis" (LVA), aimed at clearing toxic proteins from the brain to halt the progression of Alzheimer's disease and preserve cognitive function [1][4]. Regulatory Actions - The National Health Commission has issued a notice prohibiting the use of LVA for treating Alzheimer's disease, citing that the technique is still in the early exploratory stage of clinical research, with unclear indications and contraindications, and lacking high-quality evidence for safety and efficacy [1][2]. Clinical Research and Observations - Clinical trials for LVA have been conducted in two hospitals in Shanghai, with 12 patients undergoing the procedure as of June 10, 2024. Initial feedback indicates slight improvements in cognitive abilities, particularly in attention and reaction speed, with some patients experiencing temporary mental confusion post-surgery [4][5]. Expert Opinions - Some experts express skepticism about the effectiveness of LVA, suggesting that the immediate post-operative improvements may be misleading and not indicative of long-term benefits. Concerns have been raised regarding the complexity of Alzheimer's disease and the simplicity of the surgical approach [5][6][7]. Alternative Applications - LVA has also been explored for treating Parkinson's disease, with some hospitals reporting its use as an alternative to traditional deep brain stimulation methods. However, the primary treatment for Parkinson's remains deep brain stimulation [5].